His primary scientific interests are in Internal medicine, Surgery, Thrombosis, Intensive care medicine and Anticoagulant. Much of his study explores Internal medicine relationship to Cardiology. His research integrates issues of Incidence, Cohort study and Vitamin K antagonist in his study of Surgery.
His Thrombosis research includes elements of Hemostasis, Pulmonary embolism, First episode and Hazard ratio. His Intensive care medicine study incorporates themes from Dabigatran, Disease and Antithrombotic. Walter Ageno has included themes like Rivaroxaban, Warfarin and Randomized controlled trial in his Anticoagulant study.
His primary areas of study are Internal medicine, Thrombosis, Surgery, Intensive care medicine and Pulmonary embolism. His Cardiology research extends to Internal medicine, which is thematically connected. His study explores the link between Thrombosis and topics such as Anticoagulant that cross with problems in Randomized controlled trial.
His Surgery research is multidisciplinary, incorporating perspectives in Incidence, Cohort study and Warfarin. Walter Ageno has researched Intensive care medicine in several fields, including Rivaroxaban, Clinical trial, Antithrombotic, Heparin and Disease. His Confidence interval research is multidisciplinary, relying on both Odds ratio and Meta-analysis.
Walter Ageno spends much of his time researching Internal medicine, Thrombosis, Pulmonary embolism, Randomized controlled trial and Venous thromboembolism. His Confidence interval, Hazard ratio, Anticoagulant, Incidence and Cancer investigations are all subjects of Internal medicine research. His Thrombosis study combines topics in areas such as Emergency department, Retrospective cohort study and Intensive care medicine.
His study in Pulmonary embolism is interdisciplinary in nature, drawing from both Cause of death, Prospective cohort study, Cohort study and Subgroup analysis. His Randomized controlled trial research integrates issues from Meta-analysis, Propensity score matching and Heparin. His research in Venous thromboembolism focuses on subjects like Vitamin K antagonist, which are connected to Cohort, Hematology and Clinical trial.
Internal medicine, Confidence interval, Randomized controlled trial, Pulmonary embolism and Incidence are his primary areas of study. As part of his studies on Internal medicine, Walter Ageno often connects relevant areas like Placebo. His studies in Pulmonary embolism integrate themes in fields like Asymptomatic and Deep vein.
His Deep vein research is within the category of Thrombosis. The study incorporates disciplines such as Cancer and Splanchnic vein thrombosis in addition to Incidence. His Hazard ratio research is multidisciplinary, incorporating perspectives in Anticoagulant and Stroke.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli;Mahesh V. Madhavan;David Jimenez;Taylor Chuich.
Journal of the American College of Cardiology (2020)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Michael R. Lassen;Walter Ageno;Lars C. Borris;Jay R. Lieberman.
The New England Journal of Medicine (2008)
Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno;Alexander S Gallus;Ann K Wittkowsky;Mark Crowther.
Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
Walter Ageno;Cecilia Becattini;Timothy Brighton;Rita Selby.
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Cecilia Becattini;Giancarlo Agnelli;Alessandro Schenone;Sabine Eichinger.
The New England Journal of Medicine (2012)
Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism
Giancarlo Agnelli;Paolo Prandoni;Cecilia Becattini;Mauro Silingardi.
Annals of Internal Medicine (2003)
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation A Systematic Review and Meta-Analysis of the Literature
Francesco Dentali;Nicoletta Riva;Mark Crowther;Alexander G.G. Turpie.
Incidence of Chronic Thromboembolic Pulmonary Hypertension After a First Episode of Pulmonary Embolism
Cecilia Becattini;Giancarlo Agnelli;Raffaele Pesavento;Mauro Silingardi.
Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome Results of a Prospective Multicenter Study
Maurizio Paciaroni;Giancarlo Agnelli;Francesco Corea;Walter Ageno.
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists
Francesco Dentali;Chiara Marchesi;Matteo Giorgi Pierfranceschi;Mark Crowther.
Thrombosis and Haemostasis (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: